Diligence memo · auto-generated · as of July 2, 2026
Barnwell Bio, Inc.
Barnwell Bio, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Barnwell Bio, Inc. operates in Biotech / Pharma, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Barnwell Bio, Inc. has raised $6.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.1M on 2025-04-04.
Most recent recorded round closed around 2025-04-04.
Valuation (modeled)modeled
Provath models Barnwell Bio, Inc. at approximately $22M (range $6.8M–$41M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.31× the median modeled value of Series A Biotech / Pharma companies in 2025–2027 (16 peers) — value vs value, same stage and era. Within the normal band (131% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 15 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 55% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 45% of those peers.
Closest niche peers: Evio Pharmacy Solutions, LLC, Ruby Bio, Inc., Intelligent Bio Solutions Inc., Arkea Bio Corp., BroadOak Biolog, LLC.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.